ArticleOncology letters2019
Two postoperative chemotherapies for gastric cancer: FOLFOX4 vs. TPF.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 10 citations in OpenAlex.
- TPF regimen improves conversion surgery and short-term survival in patients with locally unresectable advanced gastric cancer.American journal of translational research · 2025Article
- Effect of cetuximab plus FOLFOX4 regimen on clinical outcomes in advanced gastric carcinoma patients receiving evidence-based care.World journal of clinical cases · 2024Article
- Development of a nomogram based on body composition analysis of quantitative computed tomography combined with clinical prognostic factors to predict disease-free survival after surgery and adjuvant chemotherapy in patients with gastric cancer.Quantitative imaging in medicine and surgery · 2023Article
- An Evaluation of Fluorouracil plus Paclitaxel and Oxiliplatin as a First-Line Treatment for Advanced Gastric Squamous Cell Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2023Article
- Treatment Alternative and High Safety Profile of Acupuncture Plus Chemotherapy for Advanced Gastric Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Clinical Efficacy of ModifiedEvidence-based complementary and alternative medicine : eCAM · 2022Article
- Article
- The Impact of m6A RNA Modification in Therapy Resistance of Cancer: Implication in Chemotherapy, Radiotherapy, and Immunotherapy.Frontiers in oncology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical effects of FOLFOX4 and TPF chemotherapy regimen on postoperative gastric cancer patients were investigated. A total of 60 patients admitted to the First People's Hospital of Changzhou receiving gastric cancer operation were selected and they were divided into two groups at random. Thirty patients in the FOLFOX4 group were treated with oxaliplatin, fluorouracil and leucovorin, while 30 patients in the TPF group were treated with paclitaxel, fluorouracil and cisplatin. The therapeutic effects, adverse reactions, quality of life and survival time of patients in the two groups were observed. The total effective rate of the FOLFOX4 group was 73.3%, which was significantly higher than that of the TPF group (43.3%), and the difference was statistically significant (P<0.05). The proportions of neurotoxicity and thrombocytopenia in the FOLFOX4 group were 56.7 and 33.3%, while those in the TPF group were 26.7 and 60%, respectively, and the differences were statistically significant (P<0.05). The increasing proportion of postoperative scores of the FOLFOX4 group was 46.7%, which was significantly higher than that of the TPF group (20%), and the difference was statistically significant (P<0.05). The 2- and 3-year survival rates of the FOLFOX4 group were 63.3 and 50%, which were significantly higher than those of the TPF group (36.7 and 23.3%), and the differences were statistically significant (P<0.05). Therefore, the effective rate of FOLFOX4 regimen is high in the treatment of gastric cancer with relatively fewer adverse reactions, which has a certain advantage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.